BACKGROUND: Platelet dysfunction has been described as an early component of trauma-induced coagulopathy. The platelet component of trauma-induced coagulopathy remains to be fully elucidated and translatable animal models are required to facilitate mechanistic investigations. We sought to determine if the early platelet dysfunction described in trauma patients could be recapitulated in a nonhuman primate model of polytraumatic hemorrhagic shock.
H emorrhagic shock (HS) remains the leading cause of preventable trauma-related deaths in civilian and military populations. 1, 2 The combination of severe injury and hypotension initiates a cascade of biologic events that disrupt hemostasis, in a process termed trauma-induced coagulopathy (TIC). 3 The presence of TIC on admission to the emergency department is associated with a four-fold increased mortality risk, increased blood product utilization, and organ failure. [4] [5] [6] Trauma-induced coagulopathy is a multifactorial process that disrupts hemostasis through impairments in coagulation, fibrinolysis, and platelet function. 7 Platelet dysfunction independent of platelet count has been described as an early component in the pathophysiology of TIC. [8] [9] [10] In the context of the cell-based model of hemostasis, platelets play a pivotal role in maintaining hemostasis following trauma through adhesion and aggregation to establish a hemostatic plug at the site of vessel injury and membrane amplification of coagulation protease activation of thrombus formation. 11 Platelet dysfunction can cause near-total impairment of clot formation even in the presence of normal-range platelet counts. 12 The specific mechanisms driving platelet dysfunction in TIC remain to be fully elucidated, and translatable animal models are needed to develop therapeutic strategies to attenuate the pathogenesis of these coagulation changes. Multiple animal models have been developed to study mechanisms of trauma and HS and to evaluate therapeutic agents; however, clinical translatability remains questionable owing to hematologic and physiologic disparities associated with low-order species such as rodents 13, 14 and xenogeneic complications seen in swine. [15] [16] [17] Nonhuman primates (NHP) are orthologous to humans physiologically, immunologically, and genetically, making them ideal for human disease modeling. [17] [18] [19] Furthermore, old-world monkeys (i.e., rhesus macaques) circumvent xenogeneic reactions that disrupt the evaluation of human-derived blood products in lower-order species. [15] [16] [17] We sought to determine if the early platelet dysfunction described in trauma patients could be recapitulated in an NHP model of polytraumatic HS, thereby expanding our understanding of the platelet pathophysiology and uncovering opportunities for subsequent investigations and treatment development.
METHODS

Ethical Approval and Accreditation
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the 711th Human Performance Wing, Joint Base San Antonio-Fort Sam Houston, and conducted in accordance with the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council, National Academy Press, 2011. All procedures were performed in facilities accredited by the Association for Assessment and Accreditation for Laboratory Animal Care International. This manuscript focuses on one distinct study aim of a multifaceted polytraumatic HS NHP protocol.
Preoperative Preparation
Rhesus macaques used in this study were housed in compliance with the Secretary of the Navy Instruction (SECNAVINST) 3900.38C regulations. Feed was withheld 12 hours before surgery. Twenty-four male rhesus macaques weighing 7 to 14 kg and aged 5 to 11 years were randomized into three injury cohorts (n = 8/cohort): 60-minute severe pressure-targeted controlled HS; HS + soft tissue injury (HS-ST); or HS-ST + musculoskeletal injury (HS-ST-MS), while an additional three male rhesus macaques were used as anesthesia controls (n = 3).
Anesthesia and Analgesia
Nonhuman primates were sedated with Telazol (3.0 mg/ kg; Fort Dodge Animal Health, Overland Park, KS, USA), premedicated with an analgesic (Buprenex, 0.03 mg/kg; Reckitt Benkiser, Slough, Berkshire, UK), and weighed (Detecto Scale, Webb City, MO, USA). Airway intubation was achieved with placement of a pediatric endotracheal tube (size, 4-5.5 mm; Rusch-Teleflex, Research Triangle Park, NC, USA), and placed on a Dräger Apollo Anesthesia Workstation (Draeger Medical Inc, Telford, PA, USA) with volume-controlled respiration (10 mL/kg) at 12 to 15 breaths per minute, FiO 2 of 21% to 25% and isoflurane (1.0-2.0%) inhalational anesthesia. Core body temperature was monitored continuously via 10 Fr rectal temperature probe connected to a Datex Ohmeda Cardiocap/ 5 patient monitor (GE Healthcare Systems, Wauwatosa, WI, USA) and maintained between 36.0°C and 38.0°C.
Arterial and Venous Line Placement
The right femoral artery was cannulated with a SIL-C70 silicone catheter (Solomon Scientific, Skokie, IL, USA) to facilitate blood sampling and invasive, continuous blood pressure monitoring using the Datex Ohmeda Cardiocap/5 patient monitor (General Electric Co, Fairfield, CT, USA). The right femoral vein and left femoral artery were cannulated with a 14-gauge large bore catheter (Jorgensen Laboratories, Loveland, CO, USA) for intravenous resuscitation fluid infusion and to facilitate hemorrhage, respectively.
Soft Tissue and Musculoskeletal Injury
After baseline (BSLN) blood samples were drawn, a 10-minute "injury window" was observed in all groups to standardize procedure times. Within this time frame, the randomly assigned additional tissue injury, or no injury, was produced ( Fig. 1) .
Soft tissue injury was created by a 15-cm laparotomy incision spanning from the xiphoid process toward the umbilicus. The laparotomy incision remained open during the shock period and was closed in two layers (fascia and skin) with continuous sutures during the resuscitation phase. Figure 1 . Procedure summary. Schematic depicting experimental design including time points of injury window, hemorrhage, resuscitation, and observational procedures. Whole blood was drawn for laboratory tests (complete blood cell count, arterial blood gas, and platelet impedance aggregometry analysis) at BSLN, EOS (T = 60 minutes), EOR (T = 180 minutes), and T = 360 minutes.
The musculoskeletal injury was created on the left leg using a longitudinal 5-cm incision spanning the anterior midfemur to distal femur followed by blunt dissection to separate muscle and muscle insertions from a 4-cm span over the midfemur. An oscillating power bone saw was used to transect the femur, gauze was placed in the wound for blood collection, and the skin incision was closed with staples. During the resuscitation phase, the gauze was removed and weighed to quantify blood loss, the femur was approximated and fixated with steel plates and screws, and the incision closed in two layers (fascia and skin) with sutures.
Pressure-Targeted Controlled HS
Hemorrhage was initiated by opening a stopcock in-line with the left arterial catheter allowing free flow of blood until the mean arterial pressure reached 20 mm Hg. This moment marked the beginning (T = 0 minute) of the shock period, additional blood was withdrawn as needed to maintain a mean arterial pressure of 20 to 24 mm Hg until the end of shock (EOS; T = 60 minutes). Hemorrhaged blood was collected in a blood donor bag containing anticoagulant citrate dextrose solution-solution A (ACDA-A) at a 1:10 ratio for subsequent use in resuscitation.
Standardized Resuscitation
At T = 60 minutes, blood samples were collected, and animals were then resuscitated at a constant rate with 0.9% NaCl (normal saline, 2Â shed blood volume (SBV)) infused over 30 minutes, followed by whole blood (50% SBV) infused over 30 minutes and then 1Â SBV of NS over 60 minutes. Whole blood transfusion was preceded with 100 mg/mL calcium gluconate (Vedco, Saint Joseph, MO, USA) to elevate possible calcium chelation effects of the anticoagulant. At the end of resuscitation (EOR; T = 180 minutes), animals were monitored under anesthesia until T = 360 minutes.
Laboratory Analysis
Arterial blood samples were collected at: BSLN, EOS, EOR, and T = 360 minutes.
Whole blood analysis was performed for complete blood cell count (HemaTrue; HESKA, Loveland, CO, USA) and arterial blood gas (GEM Premier 4000; Instrumentation Laboratory, Bedford, MA, USA).
Platelet aggregation was performed on whole blood by impedance aggregometry (Multiplate; Verum Diagnostica GmbH, Munich, Germany) using the agonists: adenosine diphosphate (ADP), collagen (COL), thrombin receptor-activating peptide-6 (TRAP) and arachidonic acid (AA). Agonist responses are reported as area under the aggregation curve in units (U) over a 6-minute measurement period and as non-normalized and normalized to platelet count.
Data Reporting and Statistical Analysis
Statistical analyses were performed using Prism 6 (GraphPad Software, Inc, La Jolla, CA, USA). Spearman correlations were used to correlate platelets' responsiveness to agonists with platelet count. For overall cohort analysis, normally distributed variables were expressed as mean ± standard deviation (SD) and Student t-test used for comparisons, while non-normally distributed variables were expressed as median and interquartile range (IQR) and the Wilcoxon nonparametric test was used for comparisons. For comparison between cohorts, a one-way analysis of variance and two-way repeated-measures analysis of variance were performed. A p < 0.05 was considered significant.
RESULTS
Survival, Blood Loss, and Hematological Parameters
Analysis of percent blood loss (59% ± 9% vs 52% ± 8% vs 49% ± 7% for HS, HS-ST, and HS-ST-MS, respectively) and markers of injury severity at all-time points as determined by lactate, base deficit, pH, bicarbonate anion (HCO 3 − ), partial pressure of carbon dioxide, and platelet count (Table 1) revealed no significant differences between the three injury paradigms. Possible effects of citrated whole blood transfusion were tracked with ionized calcium at all time points (BSLN, EOS, EOR, and T = 360 minutes). While levels do drop, with the nadir at EOR, by T = 360 minutes, levels begin to return to BSLN for the overall cohort (1.04 ± 0.05 vs 0.95 ± 0.07 vs 0.89 ± 0.06 vs 0.95 ± 0.06). It is important to note that our BSLN values started off at less than 1.12 mmol/L, the cutoff for hypocalcemia, but never went below 0.8 mmol/L, a marker for ionized calcium treatment. 20 Within the overall study cohort, lactate peaked at 3.1 ± 1.7 mmol/L and troughs were seen for base deficit at −7.5 ± 1.6 mmol/L, pH at 7.39 ± 0.03, HCO 3 − at 23.4 ± 1.3 mmol/L, partial pressure of carbon dioxide at 35.7 ± 6.4 mm Hg, and platelet count at 200 ± 35 Â 10 3 /μL. Subsequent analyses were done on the overall study cohort. All NHPs survived to the final time point of T = 360 minutes and never became thrombocytopenic (platelet count <100 Â 10 3 /μL) (Fig. 2) . In the overall cohort, platelet responsiveness decreased for all agonists over the course of the study compared to BSLN values (Fig. 3) . Platelet aggregation in response to ADP was measured at 25.6 U (IQR, 18.6-28. Normalized platelet aggregation data are presented in Figure 5 . Platelet responsiveness to the agonist TRAP demonstrated no change from BSLN at subsequent time points. Responsiveness to ADP was significantly less at EOR but not EOS or T = 360 minutes compared to BSLN. Platelet responsiveness to COL and AA was not significantly different at EOS compared to BSLN, however, was significantly less at EOR and T = 360 minutes.
DISCUSSION
Platelet dysfunction was observed 60 minutes after initiation of shock involving all platelet activation pathways in this NHP model of HS with tissue injury. These platelet dysfunctions were exacerbated after animals were resuscitated, and function remained significantly depressed up for 180 minutes after resuscitation from shock. While platelet counts progressively decreased during the experiment until resuscitation, none of the animals developed clinically significant thrombocytopenia (e.g., platelet count < 100,000/μL), consistent with the concept of a trauma-induced thrombasthenia. While correlations between platelet dysfunction and platelet counts were significant, normalizing platelet function to platelet count demonstrated that platelet dysfunction remained significant for specific pathways at specific time points during the experiment with the exception of the TRAP pathway.
Kutcher et al. 9 and Solomon et al., 21 reported weak correlations between platelet count and responsiveness to agonists ADP, COL, TRAP, and AA and observed platelet dysfunction in the presence of normal platelet counts. While our aggregation data reflect trauma patient observations, the significance and extent of platelet responsiveness to agonists was affected after platelet count normalization. These findings conflict with reports in the literature that suggest platelet counts in the observed range are unlikely to interfere with platelet functional analysis. 22, 23 Both COL and AA showed similar dysfunction at EOR and T = 360 minutes when non-normalized or normalized, supporting the notion that both COL and AA have important implications in trauma and have already been identified to be independent predictors of mortality in a risk-adjusted model. 9 It remains important to appreciate that the timing and partial recovery of platelet dysfunction is not identical between all platelet receptor pathways. These receptors coordinate a complex hemostasis process that dictates the platelets' adhesion, cohesion, degranulation, and contribution to clot formation. 24 Up to 92% of critically injured patients during their hospitalization will develop platelet dysfunction. 9 The ADP pathway was the first platelet dysfunction appreciated in this model that persisted to be significant after adjusting for platelet count. This is consistent with clinical studies by Wohlauer et al. 8 and Moore et al., 10 in which ADP dysfunction was appreciated in blood samples obtained before hospital or upon arrival at the emergency department in patients that had received minimal resuscitation. The mechanism driving ADP dysfunction in trauma remains elusive. Cationic metabolites such as succinate have been implicated in early ADP platelet inhibition, but not lactate. 10 This is supported by this study in which the animal's nadir of platelet function was after resuscitation when lactate levels had already normalized. There are numerous metabolic pathways that are clinically unmeasured in humans that begin to demonstrate significant changes within minutes of HS observed in a rat model. 25 Although the addition of soft tissue and femur injury caused slight dysfunction at EOS, their addition did not drastically change the pattern, and all injury cohorts demonstrated similar dysfunction by EOR. While our study focused on hemorrhage, soft tissue, and long bone injuries, there may be specific injury patterns, which also cause platelet dysfunction that were not assessed in this model; for example, ADP dysfunction in traumatic brain injury has been found to be prognostic of mortality and not dependent on hypotension. 26, 27 With respect to normalized data, there was a descending order of effect for agonists ADP, COL, and AA on platelet dysfunction at EOR, with downplay of ADP, and COL and AA demonstrating similar effects between non-normalized and normalized data. All three of these agonists lead to the production of thromboxane A2, with ADP and COL also modulating other mechanisms of activation, degranulation, and aggregation. 28, 29 These data are suggestive that resuscitation may have some effect on thromboxane A2 production or receptor binding, with thromboxane A2 receptor desensitization having been demonstrated to cause platelet dysfunction. 30, 31 In this study, the greatest dysfunction was seen in response to agonist AA, which solely examines the production of thromboxane A2 through cyclooxygenase 1. Platelet aggregation in response to TRAP remained unchanged when normalized to platelet count and is known to act independent of both thromboxane A2 and ADP pathways. 31, 32 Specifically, TRAP-induced degranulation is independent of thromboxane A2 generation, while thromboxane A2 generation is important for ADP and COL-induced degranulation. 33 This supports the notion that resuscitation affects some mechanism of the thromboxane A2 pathway. The effects of reduced aggregation to COL and AA on uncontrolled bleeding are still unknown, but this research offers an interesting insight into the role of platelet dysfunction(s) in trauma. This study demonstrates that platelet dysfunction can be reproduced in an animal model of HS and polytrauma. This reproducible model of platelet dysfunction that persists 180 minutes after resuscitation remains clinically relevant, as return to normal blood pressure does not correct the animal's platelet coagulation abnormality. With recent animal work demonstrating that platelet dysfunction precedes other manifestations of trauma-induced coagulopathy, 34 which has been already suggested in humans, 10 it is essential to increase our understanding of the role of platelet dysfunction in trauma. Arguably, the prognostic value of platelet function after minor trauma has no association with adverse outcomes and mortality. 35 There may be a protective role in having a moderate level of platelet dysfunction after trauma. However, exacerbation of this dysfunction with the inappropriate resuscitation fluid could be lethal. This has previously been demonstrated when evaluating fibrinolysis in a rodent model in which normal saline exacerbated coagulopathy while plasma resuscitation kept coagulopathy at a similar level and improved survival in a model of HS. 36 In our model, we used a NS followed by whole blood resuscitation. The component of the acute coagulopathy of resuscitation represents a promising area of investigation, as therapeutic opportunities may exist to attenuate this reperfusion coagulopathy. Additionally, it is unknown if the shock environment might render transfused platelets dysfunctional; therefore, timing of platelet transfusion for greatest effectiveness should be considered.
While the platelet dysfunction data are consistent with that seen in human trauma, the severity of our model was not. Despite profound hemodynamic shock in these NHPs, lactate levels peaked at 3.1 ± 1.7 mmol/L, and the nadir for base deficit was −7.5 ± 1.6 mmol/L; this relatively mild metabolic effect may have contributed to the milder platelet dysfunction seen at the EOS when compared to EOR. The use of normal saline as a resuscitation fluid could also be a confounding factor possibly causing hyperchloremic acidosis, which may be affecting platelet function independent of the actual shock and injury. Based on this possibility, we are currently undertaking a study to specifically look at the effect of different crystalloids on the metabolic and coagulation effects in these models.
Here, we provide a translatable model for further elucidation of the mechanism of early platelet dysfunction following trauma and for evaluating therapeutics and resuscitation strategies. We have demonstrated that in a model of HS with or without tissue injury, platelet dysfunction can be reproduced and seems to be independent of critically low platelet counts, which are used by many trauma centers to guide platelet transfusion. This animal model demonstrates numerous points of impact for therapeutic potential and investigation of the role of platelet dysfunction in trauma. AUTHORSHIP L.J.S., implemented the study, interpreted data, and drafted and critically revised the manuscript. H.B.M., interpreted data and drafted and critically revised the manuscript. A.P.C., interpreted data and critically revised the manuscript. J.J.G., interpreted data, drafted and critically revised the. E.E.M., interpreted data, drafted and critically revised the manuscript. F.R.S., principal investigator, was responsible for study conception and design, implementation of study, completion of study, interpretation of data, manuscript drafting, and critical revision.
Dr. Weidun A. Guo (Buffalo, New York): I would like to thank the AAST for the privilege to discuss this well-written manuscript by the Sheppard group. I just learned that Leasha is a pre-med student. Leasha, I compliment you on your excellent presentation.
I congratulate the authors for this forward-leaning translational research to determine the early platelet dysfunction. The study is important from both a research and clinical standpoint, because it provides a non-primate model for further understanding of the mechanisms behind this acute uncontrollable bleeding that accounts for 30-40% of patients who die in the acute phase of trauma.
The followings are my questions to the authors. My first question is in regard to the importance of the nonhuman primate model in the TIC research. Is there any data demonstrating that a rodent model is not appropriate for TIC? On the other hand, is there any human data available to be compared side-by-side with your results, before claiming that the platelet dysfunction in this non-human primate model is consistent with that in humans?
My second question relates to the body weight of the primates. The Rhesus Macaques weighed 7-14 kilograms in your study. While an adult Rhesus Macaques weighs 5-7 kg on average, was a 14 kg monkey obese or morbidly obese? If this is the case, then how could you make sure that the obesity is not a confounding factor for the coagulation abnormality?
The third question is about the blood transfusion. In your study, the primates received autologous blood which was collected during the induction of hemorrhagic shock, and later transfused back to the same individual. This is in stark contrast to what we are doing in our clinical practice, in which trauma patients receive homologous blood from human donors. Homologous blood transfusion by all means causes more immunologic reaction as compared to autologous transfusion. Could you please comment on the rationale of autologous blood transfusion in your study and the potential clinical implications?
My last question is about the hemorrhagic shock. Perhaps the most striking parameter that I found from your study is the MAP, which was only 20-24 mmHg during hemorrhagic shock. I am wondering if this scenario is translatable to hemorrhagic shock in humans, in which a MAP of 20-24 mmHg for 60 minutes is unlikely compatible with life.
Regardless of the issues raised above, I applaud the authors for their efforts in pushing the horizon and leading the way in the investigation of trauma-induced coagulopathy. I anticipate the authors will provide important future direction for improving outcomes in our patients with trauma-induced coagulopathy.
